Business Context and Reporting Period
Company: Bausch Health Companies Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year Ended December 31, 2025
Business Overview: A global, diversified specialty pharmaceutical and medical device company operating in five segments: Salix (GI), International, Solta Medical (Aesthetics), Diversified (Neurology, Dermatology, Generics, Dentistry), and Bausch + Lomb (Eye Health). The Company holds approximately 88% ownership of Bausch + Lomb Corporation and is actively pursuing a separation of the Bausch + Lomb business, contingent on debt leverage targets and shareholder approvals.
Key Financial Metrics (2025 vs. 2024)
| Metric (in millions, except per share) | 2025 | 2024 | Change |
|---|---|---|---|
| Revenues | $10,266 | $9,625 | +$641 (7%) |
| Operating Income | $1,813 | $1,546 | +$267 |
| Income Before Taxes | $367 | $167 | +$200 |
| Net Income (Loss) | $120 | $(72) | +$192 |
| Net Income Attributable to BHC | $157 | $(46) | +$203 |
| Diluted EPS | $0.42 | $(0.13) | $0.55 |
| Operating Cash Flow | $1,400 | $1,597 | $(197) |
| Total Debt Obligations (Principal) | $20,232 | $20,480 | $(248) |
| Cash & Cash Equivalents | $1,325 | $1,201 | +$124 |
Margin Analysis: Operating margin improved to 17.7% in 2025 from 16.1% in 2024. Net income margin turned positive at 1.2% compared to a loss of 0.7% in the prior year.
Material Changes and Segment Performance
- Revenue Growth Drivers: The 7% revenue increase was driven by improved net realized pricing ($303M), higher volumes ($220M), favorable foreign currency impacts ($72M), and acquisitions ($16M).
- Segment Highlights:
- Salix: Revenue increased 11% to $2,578M; Profit increased 20% to $1,925M. Xifaxan® remains the primary driver (approx. 85% of segment revenue).
- Bausch + Lomb: Revenue increased 6% to $5,101M; Profit increased 2% to $1,125M. Growth driven by volume increases across all businesses.
- Solta Medical: Revenue increased 18% to $518M; Profit increased 9% to $232M.
- Diversified: Revenue decreased 1% to $937M due to volume declines in Neuroscience and Dermatology, partially offset by pricing increases.
- Impairments: Recognized $145M in goodwill impairments (Generics reporting unit) and $8M in asset impairments in 2025. This contrasts with no goodwill impairment in 2024.
- Debt Restructuring: Executed significant refinancing in 2025, including the April 2025 Refinancing Transactions and December 2025 Exchange, extending maturities and reducing short-term cash requirements. Total debt principal decreased slightly to $20.2B.
Guidance, Outlook, and Risks
- Upcoming Impairment (Critical): Following the failure of Phase 3 clinical trials for the RED-C program (rifaximin SSD) in January 2026, the Company anticipates recognizing a goodwill impairment charge of approximately $1,400 million for the Salix reporting unit in the first quarter of 2026.
- B+L Separation: The separation of the Bausch + Lomb business remains a strategic priority but is subject to achieving targeted debt leverage ratios and regulatory approvals. Completion is not guaranteed.
- IRA Impact: Xifaxan® was selected for the second round of drug price negotiation under the Inflation Reduction Act (IRA). The negotiated price becomes effective January 1, 2027, expected to negatively impact revenues primarily in 2027.
- Generic Competition: Significant risk of generic entry for Xifaxan® (expected 2028), Trulance®, and other key products. The Company is actively litigating against generic manufacturers (e.g., Norwich, Amneal) to protect patent exclusivity.
- Legal Proceedings: Ongoing securities litigation, antitrust claims regarding generic pricing, and product liability suits (Shower to Shower® talc litigation, indemnified by Johnson & Johnson). Accrued loss contingencies totaled $178M as of year-end.
- Debt Covenants: The Company is currently in compliance with financial maintenance covenants but faces significant debt service obligations ($1.72B interest payments expected in 2026).
Investor Verification Checklist
- Salix Goodwill Impairment: Verify the magnitude and timing of the anticipated $1.4B impairment charge in Q1 2026 and its impact on the balance sheet and liquidity.
- B+L Separation Timeline: Monitor progress on debt leverage reduction and regulatory approvals required to consummate the Bausch + Lomb spin-off.
- Xifaxan® Litigation Status: Track outcomes of ongoing Paragraph IV litigation (Norwich, Amneal) which could accelerate generic entry prior to the 2028 patent expiration.
- Debt Covenant Compliance: Assess the Company's ability to meet financial covenants under the 2025 Credit Agreement given the high interest expense and potential future impairments.
- IRA Price Negotiation: Review the finalized negotiated price for Xifaxan® and model the revenue impact starting in 2027.
- Cash Flow Sufficiency: Evaluate whether operating cash flows ($1.4B in 2025) are sufficient to cover the $1.72B in expected interest payments and $58M in principal maturities for 2026 without further refinancing or asset sales.